3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Lymphoid
1
Head & Neck
1
Gastrointestinal
1
Breast
1
Conditions
Melanoma
98
Carcinoma, Non-Small-Cell Lung
32
Neoplasms
22
Neoplasm Metastasis
14
Carcinoma, Renal Cell
13
Prostatic Neoplasms
12
Lung Neoplasms
12
Small Cell Lung Carcinoma
10
Diabetes Mellitus, Insulin-Dependent, 12
10
Pancreatic Neoplasms
7
Uveal Melanoma
6
Skin Neoplasms
6
Ovarian Neoplasms
6
Brain Neoplasms
6
Advanced Cancer
6
Squamous Cell Carcinoma of Head and Neck
5
Sarcoma
5
Mesothelioma
5
Multiple Myeloma
4
Lymphoma, Non-Hodgkin
4
Lymphoma
4
Kidney Neoplasms
4
Hodgkin Disease
4
Head and Neck Neoplasms
4
Carcinoma, Transitional Cell
4
Carcinoma, Merkel Cell
4
Carcinoma, Hepatocellular
4
Carcinoma
4
Breast Neoplasms
4
Various Advanced Cancer
3
Interventions
Gemcitabine
13
Cisplatin
8
Capecitabine
8
Fluorouracil
5
pembrolizumab
4
Oxaliplatin
4
Sorafenib
3
Leucovorin
3
Erlotinib Hydrochloride
3
trametinib
2
regorafenib
2
durvalumab
2
N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine
2
Magnetic Resonance Spectroscopy
2
Lapatinib
2
trifluridine tipiracil drug combination
1
tremelimumab
1
spartalizumab
1
seribantumab
1
olutasidenib
1
olaparib
1
devimistat
1
derazantinib
1
dehydroftorafur
1
cediranib
1
cabozantinib
1
Trifluridine
1
Trastuzumab
1
Therapeutics
1
Sutures
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Bile Duct Neoplasms
×
Ipilimumab
×
Clear all
NCT03058289
2025-02-27
IT-01
Intensity Therapeutics, Inc.
Phase 1/2
Completed
111 enrolled
21 charts